| AASLD

Mikel Gastaca, Andrés Valdivieso, Javier Bustamante, José R. Fernández, Patricia Ruiz, Alberto Ventoso, Milagros Testillano, Ibone Palomares, Patricia Salvador, Mikel Prieto, Miguel Montejo, María J. Suárez, Jorge Ortiz de Urbina – 19 July 2016 – The once‐daily prolonged‐release formulation of tacrolimus has been recently related with significant graft and patient mid‐term survival advantages; however, practical information on the de novo administration after liver transplantation and longterm outcomes is currently lacking.

Reply

Read more about Reply

Wonhyo Seo, Eunjung Jo, Won‐Il Jeong – 19 July 2016

Comment on “Exosome‐mediated activation of toll‐like receptor 3 in stellate cells stimulates interleukin‐17 production by γδ T cells in liver fibrosis”

Read more about Comment on “Exosome‐mediated activation of toll‐like receptor 3 in stellate cells stimulates interleukin‐17 production by γδ T cells in liver fibrosis”

Ming Ni, Jian Gu, Jianhua Rao, Yuchun Zhang, Zheng Ding, Xuehao Wang, Ling Lu – 19 July 2016

Subscribe to

Hepatology Highlights

Instructions for authors

Notices

Masthead

Hepatology Highlights

Table of contents

Information for readers

Favorable longterm outcomes of liver transplant recipients treated de novo with once‐daily tacrolimus: Results of a single‐center cohort

Reply

Comment on “Exosome‐mediated activation of toll‐like receptor 3 in stellate cells stimulates interleukin‐17 production by γδ T cells in liver fibrosis”